Identity
- Security key
- 21681
- Ticker
- SKYE
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2014-02-24
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- SKYE
Detail
Enriched 2026-08-14 20:47
- Market cap
- $19,290,389.01
- Shares outstanding (class)
- 35,143,722
- Shares outstanding (weighted)
- 35,143,722
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 12
- Location
- SAN DIEGO, CA
- Homepage
- https://www.skyebioscience.com
- Description
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Market cap and share counts drift.